scholarly journals Commercial health insurance – a new power to push china healthcare reform forward?

2015 ◽  
Vol 18 (3) ◽  
pp. A103 ◽  
Author(s):  
R. Ma ◽  
L. Huang ◽  
D. Zhao ◽  
L. Xu
2018 ◽  
Vol 2018 ◽  
pp. 1-18 ◽  
Author(s):  
Weng I. Choi ◽  
Honghao Shi ◽  
Ying Bian ◽  
Hao Hu

Facing difficulties like increasing health burden and health inequity, China government started to promote commercial health insurance (CHI) in recent decades. Several policies and announcement have been issued to build up a favorable environment for development of commercial health insurance. Meanwhile, scholar tried to investigate the related issues in purpose to further improve the situation in China. Therefore, we performed this systematic review in order depict a comprehensive picture on the current evidence-based researches of CHI in China. We searched PubMed, ScienceDirect, and CNKI, supplemented with hand search in reference lists, for eligible studies published from 1990 January to 2018 April. Also, hand search was conducted to select suitable articles from international organization and reference list of eligible articles. Two independent reviewers extracted the data from eligible articles and input into a standardized form. Based on the inclusion criteria, 35 articles were included in this systematic review. Most of the studies were quantitative researches with topics such as the development level of commercial health insurance in China, the demand and supply issues related, and the relationship and influence of social health insurance, as well as the moral issues evolved from commercial health insurance system. In summary, CHI in China is still at the early development stage. Among those few evidence-based articles, the findings suggested several policy implication and different market strategy. With the initiation of new health reforms and implementation of taxes policy, more empirical researches should be conducted on issues relating to the practical operation of CHI.


2013 ◽  
Vol 14 (4) ◽  
pp. 432-448 ◽  
Author(s):  
Alexander Kemnitz

Abstract This study investigates competition between health insurance companies under different financing regulations. We consider two alternatives advanced in recent German healthcare reform discussions: competition by contribution rates (health contributions) and by fees (health premia). We find that contribution rate competition yields lower company profits and higher consumer welfare than premia competition when switching between insurance companies is costly.


Significance A congressional battle looms over Biden’s healthcare reform plans: elements are opposed by Republicans and progressive Democrats. Biden proposes to offer federally provided health insurance to all US citizens. Impacts Biden will use subsequent COVID-19 aid packages to advance his healthcare agenda, including funding community health centres. Biden will likely push to allow more medicine purchases from abroad, creating an opportunity for European and Asian pharma firms. Healthcare tax credits would make private healthcare more attractive and affordable for consumers. A public health insurance option would reduce the insurance risks facing private health insurers. The pharma industry will expend vast sums bankrolling politicians and lobbyists to fight Biden’s healthcare plans.


2007 ◽  
Vol 14 (3) ◽  
pp. 241-250 ◽  
Author(s):  
Harald Schmidt

AbstractAppeals to personal responsibility for health are controversial in many countries, especially in those that have publicly funded healthcare systems.In Germany, personal responsibility has traditionally been a focal point in the statutory health-insurance scheme. The most recent healthcare reform under the motto 'prevention before treatment, rehabilitation, and long term care' came into force on 1 April 2007 through the Gesetz zur Stärkung des Wettbewerbs in der gesetzlichen Krankenversicherung (GKV-WSG — "Law to strengthen competition among providers of statutory health-insurance scheme"). In significant parts, the law has given further emphasis to the role of personal responsibility. Implications of three important changes are discussed: (1) insured persons may no longer claim free treatment for complications arising from certain 'lifestyle choices'; (2) chronically ill and cancer patients face more stringent compliance requirements or face higher co-payments; and (3) insured persons may cash 'no-claim bonuses' if over at least one year they do not require hospitalisation or prescription medicines.Previous emphasis on personal responsibility has had relatively broad support in Germany. The long-term acceptability of the new measures will depend on several factors, including the structural and financial impact on different providers of statutory health insurance, and the capacities and opportunities of different groups in society to make use of the new provisions.


Sign in / Sign up

Export Citation Format

Share Document